Also Read: Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday? Patients with DMD slowly lose muscle function, resulting in the inability to walk, difficulty breathing ...

In 2013, Mesoblast bought the intellectual property of US pharma group Osiris Therapeutics in 2013, for around US$100 million ... identified strengthened heart function at 12 months among the ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

These results lend support to the function of nuclear Abl kinase in ... 4G10 monoclonal antibody against phosphotyrosine (Upstate Biotechnology, Waltham, Massachusetts), or 1 μg/ml monoclonal ...

BioArctic will cash in $100 million and is eligible to receive up to $1.25 billion in milestone payments. Another pair of collaborators in the antibody arena are British biotech Scancell ... in order ...

The solid data in mouse embryonic stem cells include separation of function mutations in IκBα to dissect its ... Samples were mounted using DAPI Fluoromount-G (Southern Biotech; Cat #0100-20).

In 2013, Mesoblast bought the intellectual property of US pharma group Osiris Therapeutics in 2013, for around US$100 million. The company receives ... But a follow-up study identified strengthened ...

in 100 μl PBS containing 50% Matrigel (BD Biosciences) were subcutaneously injected into the left and right dorsal flank of female BALB/c nude mice (4 weeks old), respectively. Drinking water ...